Led by $90m venture financing of Hyperfine Research, total medical devices industry cross border venture financing deals worth $715.46m were announced in North America in Q1 2021, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 15% over the previous quarter and a drop of 6.9% when compared with the last four-quarter average of $768.63m.
North America held a 60.63% share of the global medical devices industry cross border venture financing deal value that totalled $1.18bn in Q1 2021. With a 53.11% share and deals worth $626.67m, the US was the top country in North America’s cross border venture financing deal value across medical devices industry.
In terms of deal activity, North America recorded 31 cross border deals during Q1 2021, marking an increase of 10.71% over the previous quarter and a rise of 30.53% over the last four-quarter average. The US recorded 25 deals during the month.
North America medical devices industry cross border venture financing deals in Q1 2021: Top deals
The top five cross border venture financing deals accounted for 49.6% of the overall value during Q1 2021.
The combined value of the top five medical devices cross border venture financing deals stood at $355m, against the overall value of $715.46m recorded for the quarter.
The top five medical devices cross border deals of Q1 2021 tracked by GlobalData were:
1) Altium Capital, Axiom Associates, Colle Capital Partners, GV Management Co, Huamin Investment Management and Nextrans’ $90m venture financing of Hyperfine Research
2) The $82m venture financing of Scipher Medicine by Alumni Ventures Group, aMoon Partners, Echo Health Ventures, Khosla Ventures and Northpond Ventures
3) Ally Bridge Group and Northpond Ventures’ $68m venture financing of Syapse
4) The $65m venture financing of CorVista Health by Ambix Life Science Fund I and MedVenture Partners
5) HBM Partners, Khosla Ventures, Provenio Capital, Redmile Group, Samsara BioCapital and Verily Life Sciences’ venture financing of Genalyte for $50m.
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.